Suvaxyn PCV

RSS

adjuvanted inactivated vaccine against porcine circovirus type 2 in piglets

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Suvaxyn PCV has been withdrawn at the request of the marketing authorisation holder.

This EPAR was last updated on 15/04/2020

Authorisation details

Product details
Name
Suvaxyn PCV
Agency product number
EMEA/V/C/000149
Active substance
porcine circovirus recombinant virus (CPCV) 1-2, inactivated
International non-proprietary name (INN) or common name
adjuvanted inactivated vaccine against porcine circovirus type 2 in piglets
Species
Pigs (piglets)
Anatomical therapeutic chemical veterinary (ATCvet) codes
QI09AA07
Publication details
Marketing-authorisation holder
Zoetis Belgium SA
Revision
13
Date of issue of marketing authorisation valid throughout the European Union
24/07/2009
Contact address

Rue Laid Burniat 1
1348 Louvain-la-Neuve
Belgium

Product information

08/04/2020 Suvaxyn PCV - EMEA/V/C/000149 - R/0028

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Immunologicals

Therapeutic indication

Active immunisation of pigs over the age of three weeks against porcine circovirus type 2 (PCV2) to reduce viral load in blood and lymphoid tissues, and the lesions in lymphoid tissues associated with PCV2 infection, as well as to reduce clinical signs - including loss of daily weight gain, and mortality associated with post-weaning multisystemic wasting syndrome.

Assessment history

News

How useful was this page?

Add your rating